Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2

Marc R.J. Carlson,1 Whitney B. Pope,2 Steve Horvath,1,3 Jerome G. Braunstein,1 Phioanh Nghiemphu,4 Cho-Lea Tso,1 Ingo Mellinghoff,5 Albert Lai,4 Linda M. Liau,6 Paul S. Mischel,7 Jun Dong,1 Stanley F. Nelson,1 and Timothy F. Cloughesy4

Abstract

Purpose: Vascular endothelial growth factor (VEGF) is a potent mediator of vascular permeability. VEGF inhibition reduces edema and tumor burden in some patients with malignant glioma, whereas others show no response. The role of VEGF expression in edema production and the relationship to survival is not well understood.

Experimental Design: Using DNA microarray analysis, we examined VEGF and related gene expression in 71 newly diagnosed malignant gliomas and analyzed the relationship to edema and survival.

Results and Conclusions: VEGF expression was predictive of survival in tumors with little or no edema [Cox proportional hazard model, 6.88; 95% confidence interval (95% CI), 2.61-18.1; P < 0.0001], but not in tumors with extensive edema. The expression of several proangiogenic genes, including adrenomedullin (correlation coefficient, 0.80), hypoxia-inducible factor-1A (0.51), and angiopoietin-2 (0.44), was correlated with VEGF expression (all with P < 0.0001), whereas that of several antiangiogenic genes was inversely correlated. The expression of six genes was increased greater than 3-fold in edematous versus nonedematous tumors in the absence of increased VEGF expression. The most increased, neuronal pentraxin 2 (NPTX2, 7-fold change), was predictive of survival in tumors with the highest levels of edema, in contrast to VEGF (hazard ratio, 2.73; 95% CI, 1.49-5.02; P = 0.049). NPTX2 was tightly correlated with expression of the water channel aquaporin-3 (0.74, P < 0.0001). These results suggest that there are both VEGF-dependent and VEGF-independent pathways of edema production in gliomas and may explain why edema is not reduced in some patients following anti-VEGF treatment.

Malignant (grade III and grade IV) gliomas are heterogeneous tumors in both appearance and in gene expression (1, 2). Prognosis for these tumors remains poor. Survival of patients with newly diagnosed glioblastoma multiforme (GBM) has been reported to be 86% at 6 months, 61% at 1 year, and 26% at 2 years (3).

Several imaging features of GBM, including edema, negatively correlate with survival (4). Edema is also associated with shortened survival in grade III gliomas. The vascular endothelial growth factor (VEGF) is a key mediator of tumor angiogenesis and edema. Multiple VEGF isoforms are generated by alternative splicing, although the first five exons are conserved across all variants (5). Through the activation of receptor tyrosine kinases, VEGF impacts endothelial cell permeability, activation, survival, proliferation, invasion, and migration, all of which play a significant role in tumor progression. VEGF is also a potent mediator of vascular permeability, being 50 times more effective than histamine (6). Malignant gliomas express both VEGF and its receptors (7), and glioblastoma cell lines have been shown to secrete VEGF (8). Anti-VEGF therapy has been shown to improve survival in patients with metastatic colorectal cancer, breast cancer, and lung cancer (6).

Microarray analysis offers the ability to assess gene expression and to correlate these data with imaging features, including edema. Although many glioma patients show dramatic reduction in tumor and edema following anti-VEGF therapy, other patients show no response (9, 10). Therefore, we sought to use microarray analysis to investigate the possibility of VEGF-independent pathways linked to edema and survival in patients with malignant glioma.

Materials and Methods

Patient database. A total of 71 patients with newly diagnosed malignant gliomas were selected from the University of California at...
Los Angeles Neuro-oncology Clinic database. All patients participating in this database have signed institutional review board consent. Patients with both magnetic resonance imaging (MRI) scans and tissue available for microarray analysis were used. All GBM patients received radiation therapy. The majority were also treated with chemotherapy. No patients were treated with anti-VEGF therapy. Most grade III gliomas were treated with radiation therapy. Survival assessment was last done in November 2005. Histologic diagnosis and MRI data acquisition for this data set have been published previously (4). Briefly, for grading of edema, no detectable edema is assigned grade 0, edema extending up to 2 cm beyond the tumor margin is assigned grade 1, and edema extending more than 2 cm beyond the tumor margin is assigned grade 2. Of the 71 patients, 52 were diagnosed with GBM, and 19 with grade III gliomas. Grade III gliomas consisted of seven anaplastic astrocytomas, six anaplastic mixed gliomas, and six anaplastic oligodendrogliomas. Of the patients with grade III tumors, 6 out of 19 have died. For the GBM patients, 39 out of 52 have died. For the grade III tumor survivors, the average follow-up time is 1,436 days, with a range of 175 to 2,949 days. For GBM survivors, the average follow-up time is 888 days, with a range 116 to 1,670 days.

Microarray data. Using the TRIzol reagent (Invitrogen Life Technologies), total RNA was extracted from the tumor samples, and processed using an RNeasy column (Qiagen). cDNA and cRNA were generated using standard protocols (11). All samples were processed, scanned, and quality checked as previously described (12).

For analysis of gene expression measures, affymetrix data were normalized using the justRMA method provided by the Bioconductor group (13). Most samples were processed on the HG-U133A arrays. Recent samples were processed on the HG-U133 2.0 arrays. The two array pools were normalized as above. It was observed that the average brightness of these two pools was similar but not identical. Thus, the smaller pool was uniformly scaled to match the average brightness of the median brightness array from the larger group. Because the HG-U133A platform is a subset of the HG-U133 2.0 platform, only data from probe sets that were shared between the two platforms were used. Probe sets designed to detect VEGF expression were assessed for their ability to represent VEGF expression. All four representative probe sets behaved similarly for all tests. The probe set with the greatest sensitivity as evidenced by the largest coefficient of variation was selected to represent the results presented here.

To confirm VEGF expression levels, 25 tumor samples spanning the range of VEGF expression values were analyzed with real-time PCR. The ratio of VEGF to actin was calculated, and the Pearson correlation coefficient was determined.

Statistical analysis. The Kaplan-Meier method was used to estimate the survival distributions (14). Log-rank tests were used to test the difference between stratified survival groups. To assess which covariates affect survival, we used multivariable Cox proportional hazard models (15). Hazard ratios correspond to risk of death, and thus, an increased hazard ratio implies a worse prognosis. The proportional hazard assumption was tested using scaled Schoenfeld residuals (16). For each covariate, the relative hazard rate and the associated P value were examined. For all analyses, a P value of <0.05 was accepted as significant. Statistical analyses were carried out with the freely available software packages R.8 The relationship between edema and VEGF expression levels was cross-validated with the use of a Kruskal-Wallis test. Univariate differences in covariates were tested across categorical groupings by using the Kruskal-Wallis test (17). Distributions of covariates across categorical groupings were visualized with box plots.

Results

Verification of VEGF expression levels. Real-time PCR was used to confirm VEGF expression levels on representative tumor samples. The VEGF-to-actin expression ratios were determined

---

8 http://cran.r-project.org/
for 25 representative samples (out of 71 total). There was a good correlation between the two methods, with a Pearson correlation coefficient of 0.92.

Expression of VEGF in grade III and IV gliomas. VEGF expression was highly variable in GBM. The range of VEGF expression was 78 to 5,584 (n = 52), with a mean of 1,288 and SD of 1,206. For grade III gliomas (n = 19), the mean VEGF expression was 313 with a SD of 541. Thus, VEGF expression was ~4.1 times higher in GBM than grade III gliomas (P < 0.0001), in agreement with a previous report (18). For all malignant glioma, the median expression of VEGF was 508. Of the tumors with greater than this level of VEGF expression (n = 35), 33 were GBM.

Correlation of VEGF expression with edema. Figure 1 illustrates grading of edema, with examples of edema grades 0, 1, and 2 categorized per Materials and Methods. For grade III tumors, 79% were edema grade 0, 16% were edema grade 1, and 5% were edema grade 2. For GBM, those percentages were 23%, 23%, and 54%, respectively. For all malignant gliomas, VEGF expression was correlated with edema (Kruskal-Wallis test, P = 0.0011). When subdivided into edema grades, the mean expression of VEGF in grade 0 (n = 27) was 479 (SD, 582; range, 64-1,873), mean expression of VEGF in grade 1 (n = 15) was 1,373 (SD, 1,182; range, 84-3,605), and mean expression of VEGF in grade 2 (n = 29) was 1,359 (SD, 1,353; range 94-5,584). Note that some tumors had high levels of edema, without elevated VEGF expression. There was a large range of VEGF expression within the different edema subgroupings, particularly for tumors with grade 2 edema (Fig. 2).

VEGF expression and survival by edema grade. Next, we looked at survival curves using the Kaplan-Meier method for the different grades of edema (Fig. 3). We found that VEGF expression predicted time to survival in malignant gliomas when the edema grade 2 group was excluded (P < 0.001), that is, when there was little or no edema. This also was the case for GBM (P = 0.04; Fig. 4). For edema grade <2, the Cox proportional hazard model was 6.88 [95% confidence interval [95% CI], 2.61-18.1; P < 0.0001]. For edema grade = 2, the Cox proportional hazard ratio was not significant. For all gliomas, irrespective of edema status, the Cox proportional hazard ratio was 4.34 [95% CI, 2.24-8.43; P = 0.0007]. For edema grade <2, both VEGF (P = 0.014) and edema (P = 0.017) were independent predictors of survival in a Cox multivariable proportional hazard model using both as covariates.
Gene expression and survival in GBM. As stated above, we found a significant relationship between survival and VEGF expression in low-edema tumors, whereas high-edema tumors showed a relationship between survival and both NPTX2 and aquaporin 3 expression. Expression of several antiangiogenic genes was anticorrelated with VEGF expression: HIF-1α subunit inhibitor (HIF-1AN; -0.54, P < 0.0001), brain-specific angiogenesis inhibitor 1 (BAI1; -0.45, P < 0.0001), phosphatase and tensin homologue (PTEN; -0.36, P < 0.0001), BAI3 (-0.34, P < 0.003), somatostatin (-0.31, P < 0.008), and BAI2 (-0.25, P = 0.034).

Survival analysis showed that for tumors with edema ≤ 2, HIG-2, angiopoetin-2, IGFBP-5, IGFBP-7, neuropilin, and RBBP-8 were all significant predictors of survival, whereas HIF-1A was not. HIF-1A was significant only for the edema grade 1 group. Kaplan-Meier analysis segregated by edema grades shows the similarities between the survival curves of several of the proangiogenic genes and that of VEGF (Fig. 3).

Microarray expression data were sorted according to correlation with VEGF expression. A total of 339 probesets with >0.5 Pearson correlation coefficient, with P value < 0.0001, were identified. This list was searched for proangiogenic genes based on a recent review (19). This led to the identification of (correlation coefficients and P values in parentheses), adrenomedullin (0.80, P < 0.0001), hypoxia inducible protein-2 (HIC-2; 0.66, P < 0.0001), insulin-like growth factor binding protein 5 (IGFBP-5; 0.64, P < 0.0001), IGFBP-7 (0.59, P < 0.0001), RBBP-8 (0.55, P < 0.0001), IGFBP-5 (0.52, P < 0.0001), and hypoxia-inducible factor-1A (HIF-1A; 0.51, P < 0.0001). Another putative angiogenesis-related gene, angiopoietin-2, was less well correlated with VEGF expression (0.44, P < 0.0001).
Discussion

VEGF was originally described in the setting of brain tumors as a vascular permeability factor (21). The authors of that report hypothesized that VEGF may cause vasogenic edema in gliomas. Recently, we reported that inhibition of VEGF does indeed markedly reduce edema in patients with malignant gliomas (9). Edema causes mass effect and is associated with poor prognosis in these patients. In the same study, we found that not all patients responded to VEGF inhibition, however, suggesting that in some gliomas, edema is a result of VEGF-independent pathways.

In the current study, we used microarray data to show a large range of VEGF expression in malignant gliomas. We found that VEGF expression was correlated with edema. However, some tumors with a large amount of peritumoral edema had low levels of VEGF expression. This is consistent with our hypothesis that some gliomas cause edema through VEGF-independent pathways, potentially accounting for failure of these tumors to respond to anti-VEGF therapy.

In addition to being a potent stimulator of vascular permeability, VEGF is thought to play a pivotal role in angiogenesis in malignant gliomas (19, 22). We found that VEGF expression levels were predictive of survival independent of edema in tumors with little or no edema. This was true both for malignant gliomas and for only GBM. This supports the conclusion that whereas part of the deleterious effect of VEGF expression may be due to the promotion of edema and mass effect, other properties of VEGF, presumably its role in angiogenesis, may also contribute to shortened survival.

To investigate the mechanism underlying VEGF-induced angiogenesis, we assessed the correlation between VEGF expression and several putative pro- and antiangiogenic genes. Of these, *adrenomedullin* was the most tightly correlated with VEGF expression. This was not unexpected because both *adrenomedullin* and VEGF are thought to be induced by HIF (19), and HIF was also correlated with VEGF expression. Hypoxia seems crucial in the transformation of glial tumors into more aggressive phenotypes (reviewed in ref. 19). We found that another gene product associated with hypoxia, HIG-2, was also well correlated with VEGF expression. Others have shown a link between HIG-2 and renal cell carcinoma (23). No reports implicating HIG-2 in glioma progression have been published.

Several antiangiogenesis genes were inversely correlated with VEGF expression, including HIF-1α, BAI1-3, PTEN, and somatostatin. Interestingly, PTEN has been shown to inhibit adrenomedullin expression in glioma cell lines (24) and to increase VEGF expression in a mouse model for asthma (25). PTEN is also associated with chromosome 10q deletion and a poor prognosis (26). We analyzed the relationship between edema, survival, and the expression of these angiogenesis-related genes as we had done for VEGF. Several were significant predictors of survival, with many showing the same pattern as VEGF, that is, associated with survival in tumors with little or no edema. Correlation between VEGF expression and the expression of these angiogenesis-related genes, as well as their similar survival curves, suggests a functional relationship that merits further investigation. These findings also support the idea that angiogenesis is a result of

Table 1. Increase in gene expression between edematous and nonedematous tumors with low VEGF

<table>
<thead>
<tr>
<th>Gene</th>
<th>Fold change</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuronal pentraxin II</td>
<td>7.68</td>
<td>0.0299</td>
</tr>
<tr>
<td>Tissue inhibitor of metalloproteinase 1</td>
<td>5.69</td>
<td>0.0232</td>
</tr>
<tr>
<td>Matrix Gla protein</td>
<td>4.04</td>
<td>0.0364</td>
</tr>
<tr>
<td>CD163 antigen</td>
<td>3.80</td>
<td>0.0426</td>
</tr>
<tr>
<td>Cyclic AMP–regulated phosphoprotein, 21 kDa</td>
<td>3.47</td>
<td>0.0246</td>
</tr>
<tr>
<td>Neurofilament 3 (150 kDa medium)</td>
<td>3.02</td>
<td>0.0156</td>
</tr>
</tbody>
</table>

NOTE: Less than median VEGF expression.
the balance between pro- and antiangiogenic gene products and identifies a subset of genes that may impact survival and be more closely linked to VEGF-mediated angiogenesis in human gliomas.

Given our hypothesis that some malignant gliomas have VEGF-independent pathways leading to edema, we looked for gene expression enriched in edematous versus nonedematous tumors with low VEGF expression. This led to the identification of NPTX2, which was increased 7-fold in the edematous tumor group. This was the greatest percentage increase of all genes analyzed. NPTX2 is normally expressed in the central nervous system and is a member of a family of proteins related to C reactive protein and other acute-phase inflammatory mediators (27, 28) and, thus, is a good candidate for mediation of tumoral edema. NPTX2 was found to be correlated with edema in all gliomas and in only GBM patients. NPTX2 was not correlated with VEGF expression, supporting a VEGF-independent role for this gene product. Most importantly, increased NPTX2 was associated with poorer survival in tumors with the highest levels of edema. This is the reverse of VEGF expression, which was predictive of survival only for tumors with little or no edema. It will be of interest to determine if NPTX2 is elevated in tumors that do not respond to anti-VEGF therapy.

We also searched for genes that correlate with NPTX2 expression, looking for candidates that could be involved in edema production. This led to the identification of aquaporin 3, which was the gene with expression levels that most highly correlated (0.74, \( P < 0.0001 \)) with those of NPTX2. Aquaporin 3 is a member of a group of transmembrane proteins that act as water and solute channels and, thus, could potentially be involved in edema regulation (reviewed in ref. 29). Others have suggested a relationship between the expression of other aquaporin isoforms and edema in traumatic brain injury (30). Additionally, aquaporin-1 has been implicated in increased metastatic potential in a mouse tumor model (31) and increased in astrocytomas (32). More investigation will be required to understand the possible role of aquaporin 3 in brain edema in tumor patients, as well as its functional relationship to NPTX2. It is notable, however, that aquaporin 3 is induced by epidermal growth factor in fibroblast culture (33), and amplification of the epidermal growth factor receptor has been implicated in glioma progression (34, 35).

In conclusion, although VEGF expression is correlated with edema, it is an independent predictor of survival, presumably due to its angiogenic properties. Of the many putative pro- and antiangiogenic genes, we have found several that seem closely related to VEGF expression, suggesting these are genes involved in VEGF-mediated angiogenesis. Because VEGF expression has a greater impact on survival in tumors with little or no edema, our data support the hypothesis that VEGF may be crucial in the “angiogenic switch” that occurs when tumors degenerate into more aggressive, edema-producing phenotypes. How these genetic factors interplay with prognostically important clinical data, including age, treatment, and Karnofsky performance scale, remains to be determined, but this is a focus of ongoing investigation. Our data also suggest that VEGF-independent edema pathways may be important in limiting survival. In this exploratory study, with its limitation of small sample size, we found evidence that NPTX2 and aquaporin 3 are two gene products that merit further investigation as potential mediators of continued high-edema states.

References


Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/13/9/2592

Cited articles
This article cites 34 articles, 15 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/13/9/2592.full.html#ref-list-1

Citing articles
This article has been cited by 12 HighWire-hosted articles. Access the articles at:
/content/13/9/2592.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.